Abstract 2087
Background
The aim of this study was to determine the effect of e-mobile education on the quality of life of women diagnosed with breast cancer who received endocrine hormone therapy.
Methods
The study was conducted as a randomized controlled study between January and July 2018 in the Medical Oncology Outpatient Clinic of a state hospital in the province of Turkey.A total of 64 patients were included in the study according to the inclusion criteria of randomization, split into treatment (n = 31) and control group (n = 33).Data were collected using Patient Introductory Information Form, FACT-ES Quality of Life Scale and NCCN Distress Thermometer.The data were collected twice during the first week of the study and 12th week at the end of the study by face-to-face and/or telephone interviews.Treatment group patients were received information via mobile application for three months during which they were contacted in every 15 days; e-mobile training was provided, including information about breast cancer definition, treatment process, symptoms experienced during endocrine hormone therapy, adequate nutrition, regular physical activity and coping with stress.
Results
The mean total quality of life after e-mobile training to the treatment group was found to be significantly higher than the control group, and the mean distress score was lower than the control group (p < 0.05).For quality of life subscales of patients in the e-mobile training and treatment group; the scores of physical well-being, emotional well-being and endocrine symptoms were found to be significantly higher than the control group (p < 0.05).There was found no difference between the mean scores of social / family well-being subscale scores of the patients in the e-mobile training and treatment group and the control group.Treatment group reported that e-mobile training was “informative and useful a training” (87.1%).
Conclusions
As a result of the study, it has been concluded the quality of life of the patients increased when nurses use the e-mobile training and counseling in order to manage the disease process and symptoms of the women diagnosed with breast cancer and who are receiving endocrine hormone therapy with the help of the developing technologies and using the mobile technologies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract